You are here: Home » PTI Stories » National » News
Business Standard

Zydus Cadila gets USFDA nod for drug to treat seizures

Press Trust of India  |  New Delhi 

Friday said it has received final approval from the US health regulator to market extended-release tablets, used to treat certain types of

is an anticonvulsant agent. It works by reducing excessive nerve signals in the brain and restoring the normal balance of nerve activity.

has received the final approval from the Food and Drug Administration (USFDA) to market extended-release tablets USP in the strengths of 100 mg, 200 mg, and 400 mg, the company said in a BSE filing.

said the drug will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group has more than 248 drug approvals, and so far filed over 350 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.

Shares of Cadila Healthcare, the listed entity of the group, were trading 0.54 per cent up at Rs 323.60 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, February 08 2019. 12:30 IST